Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 5.1 GBX -1.92% Market Closed
Market Cap: 243.1m GBX
Have any thoughts about
Allergy Therapeutics PLC?
Write Note

Allergy Therapeutics PLC
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Allergy Therapeutics PLC
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Allergy Therapeutics PLC
LSE:AGY
Net Issuance of Common Stock
ÂŁ39.7m
CAGR 3-Years
1 896%
CAGR 5-Years
31%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Net Issuance of Common Stock
ÂŁ20m
CAGR 3-Years
-3%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
AstraZeneca PLC
LSE:AZN
Net Issuance of Common Stock
$36m
CAGR 3-Years
6%
CAGR 5-Years
-60%
CAGR 10-Years
-23%
Verona Pharma PLC
NASDAQ:VRNA
Net Issuance of Common Stock
$4.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Net Issuance of Common Stock
ÂŁ181.9m
CAGR 3-Years
11%
CAGR 5-Years
12%
CAGR 10-Years
71%
No Stocks Found

Allergy Therapeutics PLC
Glance View

Market Cap
243.1m GBX
Industry
Pharmaceuticals

Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.

AGY Intrinsic Value
4.28 GBX
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Allergy Therapeutics PLC's Net Issuance of Common Stock?
Net Issuance of Common Stock
39.7m GBP

Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Net Issuance of Common Stock amounts to 39.7m GBP.

What is Allergy Therapeutics PLC's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
31%

Over the last year, the Net Issuance of Common Stock growth was 512%. The average annual Net Issuance of Common Stock growth rates for Allergy Therapeutics PLC have been 1 896% over the past three years , 31% over the past five years .

Back to Top